<?xml version='1.0' encoding='utf-8'?>
<document id="20585260"><sentence text="Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects."><entity charOffset="73-82" id="DDI-PubMed.20585260.s1.e0" text="tenofovir" /></sentence><sentence text="The potential for a drug interaction between S/GSK1349572 and tenofovir disoproxil fumarate (TDF) was evaluated in an open-label, repeat dose, 3-period, drug-drug interaction study in healthy subjects"><entity charOffset="62-91" id="DDI-PubMed.20585260.s2.e0" text="tenofovir disoproxil fumarate" /><entity charOffset="93-96" id="DDI-PubMed.20585260.s2.e1" text="TDF" /><pair ddi="false" e1="DDI-PubMed.20585260.s2.e0" e2="DDI-PubMed.20585260.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20585260.s2.e0" e2="DDI-PubMed.20585260.s2.e1" /></sentence><sentence text="" /><sentence text="S/GSK1349572 was administered at 50 mg once daily for 5 days (period 1) followed by a 6-day washout period" /><sentence text=" TDF 300 mg once daily was then administered for 7 days (period 2)"><entity charOffset="1-3" id="DDI-PubMed.20585260.s5.e0" text="TDF" /></sentence><sentence text=" The combination of S/GSK1349572 and TDF was then coadministered for 5 days (period 3)"><entity charOffset="37-39" id="DDI-PubMed.20585260.s6.e0" text="TDF" /></sentence><sentence text=" Pharmacokinetic parameters were determined and compared between periods" /><sentence text="" /><sentence text="Fifteen subjects completed all periods and follow-up" /><sentence text=" S/GSK1349572 and TDF were generally well tolerated with few adverse events reported"><entity charOffset="18-20" id="DDI-PubMed.20585260.s10.e0" text="TDF" /></sentence><sentence text=" No clinically significant trends in post-dose laboratory abnormalities, vital signs, or electrocardiogram values were noted" /><sentence text=" Pharmacokinetic parameters of S/GSK1349572 and tenofovir during combination therapy were similar to those when given alone, demonstrating no significant drug interaction"><entity charOffset="48-57" id="DDI-PubMed.20585260.s12.e0" text="tenofovir" /></sentence><sentence text=" S/GSK1349572 geometric least squares mean ratios (90% confidence interval) for AUC(0-τ), Cmax, and Cτ were 1" /><sentence text="01 (0" /><sentence text="908, 1" /><sentence text="11), 0" /><sentence text="969 (0" /><sentence text="867, 1" /><sentence text="08), and 0" /><sentence text="920 (0" /><sentence text="816, 1" /><sentence text="04), respectively" /><sentence text=" Tenofovir geometric least squares mean ratios (90% confidence interval) for AUC(0-τ), Cmax, and Cτ were 1"><entity charOffset="1-10" id="DDI-PubMed.20585260.s23.e0" text="Tenofovir" /></sentence><sentence text="12 (1" /><sentence text="01, 1" /><sentence text="24), 1" /><sentence text="09 (0" /><sentence text="974, 1" /><sentence text="23), and 1" /><sentence text="19 (1" /><sentence text="04, 1" /><sentence text="35), respectively" /><sentence text="" /><sentence text="S/GSK1349572 and TDF can be coadministered without dose adjustment"><entity charOffset="17-25" id="DDI-PubMed.20585260.s34.e0" text="TDF" /></sentence><sentence text="" /></document>